CATX Perspective Therapeutics, Inc.
Price Chart
Executive Summary
Perspective Therapeutics announced the first patient dosed with [212Pb]VMT-α-NET in a new meningioma cohort of its ongoing Phase 1/2a study. This expands the pipeline beyond neuroendocrine tumors into a large, underserved indication with high SSTR2 expression, but the data are early and the stock has historically underperformed following prior reports on this ticker.
Actionable Insight
The meningioma cohort expansion is a modest pipeline de-risking event but remains early-stage. Monitor upcoming data readouts from Cohort 3 and future medical conference presentations for efficacy signals. Historical performance on CATX reports shows negative T+20 alpha, suggesting caution on near-term upside.
Key Facts
- First meningioma patient dosed with [212Pb]VMT-α-NET in Phase 1/2a study (LEMONαDE cohort).
- Meningiomas account for ~40% of all CNS tumors in the U.S.; ~20% of cases are WHO grades 2/3 with limited options.
- Interim data from NET cohorts reported at ASCO 2026; efficacy data for remaining Cohort 2 and Cohort 3 patients are pending.
- Company is a radiopharmaceutical developer using 212Pb alpha-particle therapy; market cap ~$411M.
Financial Impact
No financial data provided; early-stage clinical milestone with no revenue or guidance.
Risk Factors
- Clinical trial risks: safety, efficacy, or enrollment delays could impair value.
- Competition from other radiopharmaceutical and targeted therapies for meningioma.
- Cash burn rate and need for future financing given pre-revenue status.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305882 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
1d ago
|
Institutional Cluster
| $2.96 awaiting T+1 | awaiting T+1 | — | $2.95 (−0.34%) |
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $2.96 awaiting T+1 | awaiting T+1 | — | $2.95 (−0.17%) |
|
Jun 3, 2026
9d ago
|
Press Release
| $3.56 $3.25 | ▼ −8.71% | ▼ −9.11% | $2.95 (−17.13%) |
|
Jun 1, 2026
11d ago
|
8-K
| $3.66 $3.60 | ▼ −1.64% | ▼ −1.78% | $2.95 (−19.40%) |
|
May 21, 2026
22d ago
|
Press Release
| $3.98 $4.16 | ▲ +4.52% | ▲ +3.94% | $2.95 (−25.88%) |
|
May 18, 2026
25d ago
|
Press Release
| $3.76 $3.63 | ▼ −3.46% | ▼ −2.81% | $2.95 (−21.54%) |
|
May 11, 2026
4w ago
|
8-K
| $3.77 $3.77 | · 0.00% | ▼ −0.54% | $2.95 (−21.75%) |
|
May 4, 2026
5w ago
|
8-K
| $3.65 $3.82 | ▲ +4.66% | ▲ +3.27% | $2.95 (−19.18%) |
|
Apr 24, 2026
7w ago
|
Press Release
| $4.51 $4.27 | ▼ −5.32% | ▼ −5.49% | $2.95 (−34.59%) |
|
Apr 20, 2026
7w ago
|
Press Release
| $4.55 $4.64 | ▲ +1.98% | ▲ +2.63% | $2.95 (−35.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access